Researchers have developed a “polypill”—a three-drug medication that can prevent secondary adverse outcomes of myocardial infarction (MI) such as cardiovascular death, nonfatal type 1 MI, nonfatal ischemic stroke, and urgent revascularization. The current standard therapy comprises three different medications, which leads to lower patient adherence over time. Study details Phase 3 clinical trial The participants included 2499 patients with a history of MI in the past six months. The adverse outcome incidence was 9.5% with polypill and 12.7% with standard therapy.
Treatment with the polypill comprising aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction achieved a significantly lower risk of major adverse cardiovascular events as compared to the standard therapy. ##Reference## Jose M. Castellano et al. Polypill Strategy in Secondary Cardiovascular…
